Chemotherapy-induced peripheral neuropathy: Current status and progress

Gynecologic Oncology

Volumn 140, Issue 1, 2016, Pages 176-183

  Brewer, Jamie R ^a   Morrison, Gladys ^b   Dolan, M Eileen ^b   Fleming, Gini F ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemotherapy; Neuropathy; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; NEUROTROPIC AGENT; TAXANE DERIVATIVE; DOCETAXEL; PACLITAXEL; TAXOID;

BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL ASSESSMENT TOOL; DRUG INDUCED DISEASE; HUMAN; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BIOLOGICAL MODEL; CHEMICALLY INDUCED; NERVE CELL; NEURAL STEM CELL; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MODELS, NEUROLOGICAL; NEURAL STEM CELLS; NEURONS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; TAXOIDS;

EID: 84952638602     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.11.011     Document Type: Review

References (70)

1. P. Alberti, and et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin Ann. Oncol. 25 1 2014 257 264
2. W.P. Tew, and et al. Breast and ovarian cancer in the older woman J. Clin. Oncol. 32 24 2014 2553 2561
3. S.M. Lichtman, and et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 Ann. Oncol. 23 3 2012 632 638
4. S.B. Park, and et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis CA Cancer J Clin 63 6 2013 419 437
5. S. Quasthoff, and H.P. Hartung Chemotherapy-induced peripheral neuropathy J. Neurol. 249 1 2002 9 17
6. V. Chaudhry, and et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies Ann. Neurol. 35 3 1994 304 311
7. F.H. Hausheer, and et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy Semin. Oncol. 33 1 2006 15 49
8. B.P. Schneider, and et al. Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOG-1199 2015
9. R.M. Baldwin, and et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101 Clin. Cancer Res. 18 18 2012 5099 5109
10. D.L. Hertz, and et al. Genetic heterogeneity beyond CYP2C8∗3 does not explain differential sensitivity to paclitaxel-induced neuropathy Breast Cancer Res. Treat. 145 1 2014 245 254
11. D.L. Hershman, and et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline J. Clin. Oncol. 32 18 2014 1941 1967
12. E.M. Smith, and et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial JAMA 309 13 2013 1359 1367
13. S. Pignata, and et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol. 15 4 2014 396 405
14. N. Katsumata, and et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 9698 2009 1331 1338
15. A.D. Seidman, and et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J. Clin. Oncol. 26 10 2008 1642 1649
16. A.A. Argyriou, and et al. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies J. Neurol. 252 12 2005 1459 1464
17. S. Pignata, and et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study BMC Cancer 6 2006
18. P. de la Morena Barrio, and et al. Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes J. Natl. Compr. Cancer Netw. 13 4 2015 417 423
19. B.N. Reeves, and et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1 Cancer 118 20 2012 5171 5178
20. P.A. Vasey, and et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J. Natl. Cancer Inst. 96 22 2004 1682 1691
21. W.J. Gradishar, and et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 31 2005 7794 7803
22. A. Avan, and et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future Oncologist 20 4 2015 411 432
23. G. Cavaletti, P. Alberti, and P. Marmiroli Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics Lancet Oncol. 12 12 2011 1151 1161
24. C.R. Cashman, and A. Hoke Mechanisms of distal axonal degeneration in peripheral neuropathies Neurosci. Lett. 596 2015 33 50
25. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat. Rev. Cancer 4 4 2004 253 265
26. S.J. Flatters, and G.J. Bennett Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction Pain 122 3 2006 245 257
27. J.F. Kidd, and et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore J. Biol. Chem. 277 8 2002 6504 6510
28. M. Carre, and et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel J Biol Chem 277 37 2002 33664 33669
29. C.M. Peters, and et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat Brain Res. 1168 2007 46 59
30. W. Grisold, G. Cavaletti, and A.J. Windebank Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention Neuro-Oncology 14 Suppl. 4 2012 iv45 iv54
31. J.S. Gill, and A.J. Windebank Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle J. Clin. Invest. 101 12 1998 2842 2850
32. E.S. McDonald, and et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity Neurobiol. Dis. 18 2 2005 305 313
33. A.A. Argyriou, and et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature Cancer Manag. Res. 6 2014 135 147
34. A. Scuteri, and et al. Role of MAPKs in platinum-induced neuronal apoptosis Neurotoxicology 30 2 2009 312 319
35. W.H. Xiao, H. Zheng, and G.J. Bennett Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel Neuroscience 203 2012 194 206
36. L.J. Leandro-Garcia, and et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy Clin. Cancer Res. 18 16 2012 4441 4448
37. H.E. Wheeler, and et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy Clin. Cancer Res. 19 2 2013 491 499
38. M. Komatsu, and et al. Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy Clin. Cancer Res. 2015
39. A. Chhibber, and et al. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (alliance) Pharm. J. 14 4 2014 336 342
40. J. Oldenburg, and et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study J. Transl. Med. 5 2007 70
41. A.V. Khrunin, and et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients Pharm. J. 10 1 2010 54 61
42. L.B. Travis, and et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics J. Natl. Cancer Inst. 106 5 2014
43. H.L. McLeod, and et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741 J. Clin. Oncol. 28 20 2010 3227 3233
44. H.H. Won, and et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients Cancer 118 11 2012 2828 2836
45. S. Terrazzino, and et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis J. Peripher. Nerv. Syst. 20 1 2015 15 23
46. G. Cavaletti, and et al. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol Exp. Neurol. 133 1 1995 64 72
47. M.S. Wang, and et al. The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy Ann. Neurol. 50 6 2001 773 779
48. A. Hoke Animal models of peripheral neuropathies Neurotherapeutics 9 2 2012 262 269
49. S.C. Apfel, and et al. Nerve growth factor prevents toxic neuropathy in mice Ann. Neurol. 29 1 1991 87 90
50. G. Melli, and et al. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration Neurobiol. Dis. 24 3 2006 525 530
51. C.C. Verstappen, and et al. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation Anticancer Res. 24 4 2004 2337 2341
52. M. Takeshita, and et al. The pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite outgrowth but not cell death in differentiated PC12 cells Chem. Res. Toxicol. 24 11 2011 1845 1852
53. T. Kawashiri, and et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model Eur. J. Pain 15 4 2011 344 350
54. L.M. Mendonca, and et al. Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells Neurotoxicology 34 2013 205 211
55. D.R. Pachman, and et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment Clin. Pharmacol. Ther. 90 3 2011 377 387
56. J. Sandoe, and K. Eggan Opportunities and challenges of pluripotent stem cell neurodegenerative disease models Nat. Neurosci. 16 7 2013 780 789
57. B.J. Wainger, and et al. Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts Nat. Neurosci. 18 1 2015 17 24
58. H.E. Wheeler, and et al. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells PLoS One 10 2 2015 e0118020
59. B. Diouf, and et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia JAMA 313 8 2015 815 823
60. G. Cavaletti, and et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools Eur. J. Cancer 46 3 2010 479 494
61. H.Q. Huang, and et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study Int. J. Gynecol. Cancer 17 2 2007 387 393
62. T.J. Postma, and et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 Eur. J. Cancer 41 8 2005 1135 1139
63. A.C. Dueck, and et al. Validity and Reliability of the US National Cancer Institute's Patient-reported Outcomes Version of the common Terminology Criteria for Adverse Events (PRO-CTCAE) JAMA Oncol. 2015
64. K. Shimozuma, and et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 Support Care Cancer 17 12 2009 1483 1491
65. C.M. Driessen, and et al. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure Support Care Cancer 20 4 2012 877 881
66. S.B. Park, and et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy Brain 132 Pt 10 2009 2712 2723
67. J. Ferrier, and et al. A polyamine-deficient diet prevents oxaliplatin-induced acute cold and mechanical hypersensitivity in rats PLoS One 8 10 2013 e77828
68. L.E. Ta, and et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy PLoS One 8 1 2013 e54161
69. A.J. Vickers, and et al. Acupuncture is a feasible treatment for post-thoracotomy pain: results of a prospective pilot trial BMC Anesthesiol. 6 2006 5
70. J.H. Kim, P.M. Dougherty, and S. Abdi Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy Gynecol. Oncol. 136 3 2015 453 459